



Alana Miller  
National Institute for Clinical Excellence  
MidCity Place  
71 High Holborn  
London WC1V 6NA

24<sup>th</sup> January 2006

Dear Ms Miller

**HTA – Docetaxel for the treatment of hormone refractory prostate cancer - ACD**

Thank you very much for inviting our comment on the above ACD. We consider that this is a good document, that has taken into account the available evidence, and that the provisional recommendations are a sound basis for guidance to the NHS.

We would echo some previous comments regarding the difficulty faced by non-health economists in evaluating complex health economic assessments, but would stress that this is a general point and not intended as a critique of this particular ACD.

We would be delighted to provide any further assistance if required.

Yours sincerely

Malcolm Mason  
Chairman